ClinicalTrials.gg
CompletedNCT06441227Updated Apr 29, 2025

Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects

A Phase 1 interventional study of HRS-5346 tablets and placebo in Lipoprotein Disorder Disease, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled phase I clinical study. The primary objective is to evaluate the safety, tolerability, PK, and PD of single- and multiple-dose HRS-5346 in healthy subjects, and to evaluate the food effects on PK of HRS-5346.

02

Conditions studied

  • Lipoprotein Disorder Disease
03

In context

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the specific process of the test, voluntarily participate in this test, and sign the in writing.
  2. Age ≥ 18 and ≤ 55 years old on the day of signing the informed consent (including boundary value).
  3. Male subjects weigh ≥ 50 kg, female subjects weigh ≥ 45kg, and is in the range of 19\~30 kg/m2 (including boundary values).
  4. Subjects (including partners) are willing to voluntarily take effective measures within 6 months from the time of signing the informed consent form to the last time the drug is given; the female subject's blood pregnancy test must be negative and non-lactation.
  5. Normal or abnormality such as vital signs, physical examination and laboratory examination have no clinical significance.

Exclusion criteria

Exclusion Criteria:

  1. Those who suffer from any serious clinical diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease or medical history that can interfere with the test results or any significant laboratory abnormality that is judged by researchers to be of clinical significance.
  2. Previous history of malignant tumors.
  3. Those who have taken any prescription drugs, over-the-counter drugs and Chinese herbs within 14 days before taking the study drug, or within 5 half-life of the drug at the time of screening; those who plan to take non-study drugs during the trial period.
  4. Those who have participated in the clinical trial of any drug or medical device within 3 months before screening, or have not been within 5 half-life of the drug before screening (when both standards are met, the standard shall be based on the long-term standard).
  5. Subjects received siRNA in the past 12 months, or antisense oligonucleotide drugs in the past six months.
  6. The abnormal upper limit of hypersensitive C-reactive protein during the screening period is >1.5 times the normal upper limit, or the normal upper limit of /international standard ratio (PT/INR), activated partial thrombin time (aPTT) > 1.25 times normal upper limit.
  7. Screening for infectious diseases during the screening period (including virus surface antigen, virus antibody, antibody, syphilis spirochete antibody).
  8. 12-lead abnormal and clinical significance, or electrocardiogram (QTcF) male > 450 ms, female > 470 ms.
  9. The total amount of blood donated or blood loss ≥ 200 mL within 1 month before administration, or the total amount of blood donation or blood loss ≥ 400 mL within 3 months before administration, or received blood transfusion within 8 weeks.
  10. Those who have a serious infection, serious trauma or major surgery within 3 months before administration; those who plan to undergo surgery within two weeks during and after the end of the trial.
  11. Suspected people with a history of allergy to research drugs or any ingredients in research drugs, allergies or previous history of serious drug allergies.
  12. People who have had blood collection difficulties or cannot tolerate venous punctures in the past, such as needle fainting and blood fainting.
  13. (eGFR) is lower than GFR 60 mL/min/1.73 m2.
  14. Smoke an average of ≥ 5 cigarettes per day in the first three months of administration; the average daily intake of alcohol in the first month before administration exceeded 15 grams.
  15. Screening and visiting drug screening test is positive or alcohol breath test is positive.
  16. Other circumstances in which the researcher believes that the subject is not suitable to participate in this experiment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Part 1

    HRS-5346 tablets or placebo single dose

    Drug: HRS-5346 tablets · Drug: placebo

  • Experimental
    Part 2

    HRS-5346 tablets or placebo single dose with food effects

    Drug: HRS-5346 tablets · Drug: placebo

  • Experimental
    Part 3

    HRS-5346 tablets or placebo multiple doses

    Drug: HRS-5346 tablets · Drug: placebo

Interventions

  • Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

  • Drugplacebo

    Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

06

What researchers measure

Primary outcomes

  1. Assess the incidence and severity of adverse events in healthy subjects after single and multiple doses of HRS-5346 tablets

    Time frame: About three months from the first medication to the evaluation

Secondary outcomes

  1. Evaluation of AUC0-t of HRS-5346 in plasma and urine

    Time frame: About three months after the first dose

  2. Evaluation of AUC0-inf of HRS-5346 in plasma

    Time frame: About three months after the first dose

  3. Evaluation of Tmax of HRS-5346 in plasma

    Time frame: About three months after the first dose

  4. Evaluation of Cmax of HRS-5346 in plasma

    Time frame: About three months after the first dose

  5. Evaluation of t1/2 of HRS-5346 in plasma

    Time frame: About three months after the first dose

  6. Evaluation of CL/F of HRS-5346 in plasma

    Time frame: About three months after the first dose

  7. Evaluation of Vz/F of HRS-5346 in plasma

    Time frame: About three months after the first dose

  8. Evaluation of Ae of HRS-5346 in urine

    Time frame: About three months after the first dose

  9. Evaluation of fe of HRS-5346 in urine

    Time frame: About three months after the first dose

  10. Evaluation of CLR of HRS-5346 in urine

    Time frame: About three months after the first dose

07

Study locations

1 site
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 215008, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Jan 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 4, 2024
StartActual
Jun 13, 2024
Primary completionActual
Jan 9, 2025
CompletionActual
Jan 9, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06441227
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jun 13, 2024
Primary completion
Jan 9, 2025
Completion
Jan 9, 2025
Last update
Apr 29, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5346

Start the discussion